Growth hormone deficiency (GHD) is a complex disorder that can present in childhood or adulthood and results in growth failure along with more serious complications, including delayed bone age, increased adiposity, and systemic symptoms. This activity reviews the complex management of GHD, from diagnosis through treatment. The activity also reviews the wide array of established and novel recombinant growth hormone therapy options, including long-acting growth hormone treatments. Strategies for shared decision making are also discussed, along with recommendations for transitioning patients from pediatric to adult care.
0.50 AMA PRA Category 1 CreditsTM
This activity is intended for a national audience of pediatric and adult endocrinologists, pediatricians, and other clinicians involved in the management of patients with growth/growth hormone deficiencies.
This activity is supported by an educational grant from Ascendis Pharma, Inc.
Vaneeta Bamba, MD
Medical Director, Diagnostic and Research Growth Center
Director, Turner Syndrome Program
Associate Professor of Clinical Pediatrics
Division of Endocrinology
Perelman School of Medicine at the University of Pennsylvania
- Implement shared decision-making to help patients select a somatropin product based on patient characteristics and needs and product labeling
- Initiate, titrate and monitor somatropin in patients based on patient response and tolerability
- Describe the safety and efficacy of emerging long-acting recombinant human growth hormone therapies and their potential use in clinical practice
Vaneeta Bamba, MD
Advisory Board: Novo Nordisk
Accreditation and Certification
The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Additional Content PlannersJessica Martin, PhD (Medical Writer)
No significant relationships to disclose.
Annenberg Center for Health Sciences
Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.